Last $6.27 USD
Change Today +0.09 / 1.46%
Volume 2.5K
SCMP On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 10:19 AM 07/22/14 All times are local (Market data is delayed by at least 15 minutes).

sucampo pharmaceuticals-cl a (SCMP) Snapshot

Open
$6.21
Previous Close
$6.18
Day High
$6.30
Day Low
$6.21
52 Week High
01/15/14 - $11.00
52 Week Low
09/3/13 - $5.40
Market Cap
277.5M
Average Volume 10 Days
82.9K
EPS TTM
$0.24
Shares Outstanding
44.3M
EX-Date
--
P/E TM
26.1x
Dividend
--
Dividend Yield
--
Current Stock Chart for SUCAMPO PHARMACEUTICALS-CL A (SCMP)

sucampo pharmaceuticals-cl a (SCMP) Related Businessweek News

No Related Businessweek News Found

sucampo pharmaceuticals-cl a (SCMP) Details

Sucampo Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, discovery, development, and commercialization of proprietary drugs based on prostones and other drug technologies in the Americas, Europe, and Asia. It is developing and/or commercializing prostone-based drugs to treat gastrointestinal, ophthalmic, neurologic, and oncology-based inflammatory disorders, as well as for other therapeutic applications. The company, through its collaboration and license agreement with Takeda Pharmaceutical Co., Ltd., offers AMITIZA in the United States for the treatment of chronic idiopathic constipation in adults; irritable bowel syndrome with constipation in adult women; and opioid-induced constipation in adults with chronic non-cancer pain. It also provides AMITIZA in Japan through its collaboration and license agreement with Abbott Japan Co., Ltd., for chronic constipation in adults; and in the United Kingdom and Switzerland for the treatment of chronic idiopathic constipation. In addition, the company markets RESCULA in the United States for the treatment of open-angle glaucoma and ocular hypertension. Its pipeline also includes AMITIZA, which is in Phase III trial for pediatric functional constipation. The company’s other pipeline products consist of IV Ion Channel Activator, which is in Phase IIa clinical trial for the treatment of Lumbar spinal stenosis; PO Ion Channel Activator that is in Phase Ia trial for the treatment of Lumbar spinal stenosis; and cobiprostone, which has completed Phase I clinical development for the treatment of oral mucositis. Sucampo Pharmaceuticals, Inc. was founded in 1996 is headquartered in Bethesda, Maryland.

77 Employees
Last Reported Date: 03/12/14
Founded in 1996

sucampo pharmaceuticals-cl a (SCMP) Top Compensated Officers

Co-Founder, Chairman Emeritus and Scientific ...
Total Annual Compensation: $593.5K
Chief Financial Officer
Total Annual Compensation: $336.0K
Senior Vice President of Sales & Marketing an...
Total Annual Compensation: $242.8K
Chief Legal Officer, Executive Vice President...
Total Annual Compensation: $338.9K
Principal Accounting Officer
Total Annual Compensation: $273.9K
Compensation as of Fiscal Year 2013.

sucampo pharmaceuticals-cl a (SCMP) Key Developments

Sucampo Pharmaceuticals, Inc. Announces Swissmedic Approves AMITIZA 24 Mcg Treatment

Sucampo Pharmaceuticals, Inc. announced that Swissmedic, the Swiss Agency for Therapeutic Products, has approved AMITIZA (lubiprostone) 24 mcg for the treatment of opioid-induced constipation (OIC) in adults with chronic, non-cancer pain. This is the second indication approved in Switzerland for AMITIZA, which is also approved for the treatment of chronic idiopathic constipation (CIC). Opioid-based medicines are widely used in the management of chronic pain, with OIC being a common adverse effect of chronic opioid use. OIC is characterized by infrequent and incomplete evacuation of stool, hard stool consistency, and straining associated with bowel movements. Scientific literature indicates that there are approximately 98,000 patients in Switzerland each year suffering from chronic non-cancer related pain, of which approximately 62,000 require treatment for OIC. The company first received Swiss marketing authorization in November 2009 for the use of AMITIZA in the treatment of patients with CIC. Over 8 million prescriptions of AMITIZA have been filled globally since 2006.

Sucampo Pharmaceuticals, Inc. Presents at Jefferies 2014 Global Healthcare Conference, Jun-05-2014 12:30 PM

Sucampo Pharmaceuticals, Inc. Presents at Jefferies 2014 Global Healthcare Conference, Jun-05-2014 12:30 PM. Venue: Grand Hyatt, New York, New York, United States. Speakers: Cary J. Claiborne, Chief Financial Officer, Peter S. Greenleaf, Chief Executive Officer and Director, Silvia Taylor, Senior Vice President of Investor Relations, Public Relations and Corporate Communications.

Sucampo Pharmaceuticals, Inc. Reports Unaudited Consolidated Financial Results for the First Quarter Ended March 31, 2014; Provides Earnings Guidance for the Year 2014

Sucampo Pharmaceuticals, Inc. reported unaudited consolidated financial results for the first quarter ended March 31, 2014. The company reported net income of $0.7 million, or $0.02 per basic and diluted share, compared to a net loss of $3.1 million, or $0.08 per basic and diluted share, in the same period in 2013. Total revenues were $22.2 million compared to $16.9 million in the same period in 2013, an increase of 31%. The increase was primarily due to the higher royalty revenue on AMITIZA net sales in the U.S. and the growth of AMITIZA sales in Japan, partially offset by lower reimbursements from Takeda on clinical development studies. Income from operations was $2.605 million compared to loss from operations of $2.608 million a year ago. Income before income taxes was $1.939 million compared to loss before income taxes of $2.003 million a year ago. Capital expenditures were $41 million compared to $120 million a year ago. The company provided earnings guidance for the year 2014. The company now expects full year 2014 GAAP net income to be in the range of $3.0 million to $5.0 million, or $0.06 to $0.11 per diluted share.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SCMP:US $6.27 USD +0.09

SCMP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cumberland Pharmaceuticals Inc $4.52 USD 0.00
Momenta Pharmaceuticals Inc $11.14 USD +0.15
Nektar Therapeutics $11.20 USD +0.25
Progenics Pharmaceuticals Inc $5.10 USD +0.17
SciClone Pharmaceuticals Inc $5.05 USD +0.0747
View Industry Companies
 

Industry Analysis

SCMP

Industry Average

Valuation SCMP Industry Range
Price/Earnings 26.1x
Price/Sales 2.8x
Price/Book 4.1x
Price/Cash Flow 26.7x
TEV/Sales 1.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SUCAMPO PHARMACEUTICALS-CL A, please visit www.sucampo.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.